Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials

CONCLUSION: Most studies suggested that upadacitinib has no statistically significant difference in the studied safety outcomes compared to active treatments or placebo in patients with RA, PsA, AS, AD, UC, and CD. A few studies reported higher rates, but findings were inconsistent with limited interpretation.PMID:38169057 | DOI:10.1007/s12325-023-02732-6

Source: Adv Data - January 3, 2024 Category: Epidemiology Authors: Eduardo Mysler Gerd R Burmester Christopher D Saffore John Liu Lani Wegrzyn Chelsey Yang Keith A Betts Yan Wang Alan D Irvine Remo Panaccione Source Type: research